I don't disagree. I did have another bio med company and that went the same way and then exploded on a takeover. I would say from my experience it tends to go down and not up straight after consolidation. The canary in the gold mine is that we are profitable and under valued per share. In guessing 0.005 profit per share this year so PE 10 would suggest 5c valuation not 3c. 1/40 would see about 105,000,000 shares in issue so more like $2 a share on estimated profit FY 24/25. My experience would suggest we will trade at $1.20 to start and travel lower until we start reporting noticeable profit YoY.
Spit balling, the low parcel shares are taken out and then we then get a full AAR takeover offer at $2 a share. Which looks like a decent offer from under $1 but low balls our true value.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)